Skip to main content

Sequence sPecific ELImination of shiga-Toxin E. Coli

Project description

A pioneering antibiotic against toxic bacteria enters clinical trials

Escherichia coli (E. coli), a diverse group of bacteria normally found in the intestines, are mostly harmless while some are gut-friendly and beneficial to our health. However, among them, Shiga toxin-producing E. coli (STEC) are most commonly linked to foodborne outbreaks. Currently, treatment addresses only symptoms but not the cause of the illness. This may soon change thanks to the EU-funded SPELITEC programme as preclinical and clinical trials of a potent STEC eliminator will soon be underway. The drug stop STEC in its tracks without the release of the toxin into the intestines. Even better, it does not affect normal intestinal microorganisms or induce antibiotic resistance.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

ELIGO BIOSCIENCE
Net EU contribution
€ 2 763 775,00
Address
29 Rue Faubourg Saint Jacques Pepin
75014 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 2 763 775,00